Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients

Antares Pharma, Inc. announced today positive results from its Phase 3 study of Anturol Gel in patients with overactive bladder. The study met its primary endpoint of a statistically significant reduction in urinary incontinence episodes for both doses studied.

28 Jul 2010

Female sexual dysfunction can affect quality of life: Research

Almost two-thirds of females attending a general urology practice reported that they suffered from sexual dysfunction, according to a paper in the August issue of BJUI. Dysfunction rose with age in all categories except orgasm, with more than half of women aged from 18 to 30 reporting orgasm problems, significantly higher than women aged 31 to 54.

27 Jul 2010

Ampio finalizes negotiations to acquire DMI BioSciences

Ampio Pharmaceuticals, Inc. today announced it has finalized negotiations with the directors of DMI BioSciences, Inc. (DMI) to acquire DMI BioSciences, Inc. This acquisition will give Ampio access to all rights, royalties and patents associated with DMI's major assets, drugs for male sexual dysfunction including premature ejaculation (PE) and combination drugs to treat premature ejaculation and erectile dysfunction (ED).

27 Jul 2010

Euthymics Bioscience completes $24 million Series A financing

Euthymics Bioscience, Inc., a clinical-stage company developing next-generation antidepressants, today announced the completion of a Series A financing -- led by Novartis Venture Funds and Venture Investors - for a total investment commitment of $24 million in milestone-conditioned tranches. Hambrecht & Quist Capital Management, LLC, GBS Venture Partners and the State of Wisconsin Investment Board also participated in the financing.

22 Jul 2010

Clinical trial initiated to evaluate LibiGel on cognitive function in menopausal women

BioSante Pharmaceuticals, Inc. today announced the initiation of a LibiGel (testosterone gel) clinical trial to evaluate its effect on cognitive function in menopausal women. The trial is a randomized, 6-month comparison of the effect of LibiGel compared to placebo treatment on a variety of learning and memory tasks. The study is being conducted by Dr. Susan Davis, Professor of Women's Health, Department of Medicine, Monash University Women's Health Program in Australia.

13 Jul 2010

Depression increases cardiovascular problems in men with erectile dysfunction

A new study in the Journal of Sexual Medicine found that the presence of depressive symptoms in men with erectile dysfunction constitutes a risk factor for a major cardiovascular event.

13 Jul 2010

Women aged 27-45 have heightened sex drive in response to dwindling fertility: Study

As more women wait until their 30s and 40s to have children, they are more willing to engage in a variety of sexual activities to capitalize on their remaining childbearing years, according to new research by psychologists at The University of Texas at Austin.

8 Jul 2010

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

BioSante Pharmaceuticals, Inc. announced today positive results in a Phase II study of the Pill-Plus "triple hormone" oral contraceptive (OC). Results showed an increase in the frequency of sexual activity (p< 0.05) and reduced frequency of rejection of initiation of sexual activity by partner (p< 0.05).

30 Jun 2010

BioSante joins Russell 3000 Index

BioSante Pharmaceuticals, Inc. today announced it has been added to the broad-market Russell 3000 Index as part of Russell Investments' recent reconstitution of its comprehensive set of U.S. and global equity indexes which occurred after market close on June 25, 2010.

28 Jun 2010

Palatin announces completion of patient dosing, database lock in bremelanotide study for ED

Palatin Technologies, Inc. today announced the completion of patient dosing and database lock in a double-blind, placebo-controlled, multiple dose, crossover study of bremelanotide, its subcutaneously administered melanocortin agonist for treatment of erectile dysfunction (ED). Palatin expects to report top-line data in the next calendar quarter.

24 Jun 2010

Health Canada issues Screening Acceptance Letter in connection with NexMed's NDS for Vitaros

NexMed, Inc., a specialty CRO with a pipeline of product candidates based on the NexACT technology, today announced that Health Canada has confirmed acceptance of the Company's CMC response for review. The Screening Acceptance Letter from Health Canada was issued in connection with its New Drug Submission for Vitaros, the Company's topical treatment for erectile dysfunction.

24 Jun 2010

BioSante closes $15 million registered direct offering

BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

24 Jun 2010

Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH

Nymox Pharmaceutical Corporation is pleased to report positive new results from the 48-60 month follow-up study of patients treated with NX-1207 in Study NX02-0014. The initial study, completed in the U.S. in 2006, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days post-treatment with NX-1207 2.5 mg.

23 Jun 2010

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

BioSante Pharmaceuticals, Inc. commented today that the recommendation on June 18, 2010 by the FDA Advisory Committee regarding the safety and efficacy of flibanserin (Boehringer-Ingelheim) will have no impact on its own ongoing development program or approval pathway for LibiGel (testosterone gel), for the treatment of hypoactive sexual desire disorder (HSDD).

22 Jun 2010

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.

21 Jun 2010

BioSante announces $15 million registered direct offering

BioSante Pharmaceuticals, Inc. today announced that it has received commitments from several institutional investors to purchase $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante expects to receive net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

21 Jun 2010

BioSante announces presentation of LibiGel safety update at ENDO 2010

BioSante Pharmaceuticals, Inc., will present a LibiGel safety update at the 2010 Annual Meeting of the Endocrine Society (ENDO), being held from June 19-22, 2010 in San Diego, California.

18 Jun 2010

Obesity linked to bad sexual health: French Study

Now French researchers have found a link between obesity and bad sexual health in their study of 12,364 men and women aged 18 to 69 ranging from normal weight to obese who lived in France in 2006.

17 Jun 2010

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced results from a pre-clinical study showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT®, results in a topical treatment which shows bioequivalecy in efficacy to Talconex®, one of the leading topical treatments marketed for patients with mild to moderate psoriasis.

16 Jun 2010

Nymox near completion of new NX-1207 follow-up study for BPH

Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH). Nymox expects to report final results and statistical analysis for the study in the next 1-2 weeks. The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207.

16 Jun 2010

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients

Female sexual dysfunction can affect quality of life: Research

Ampio finalizes negotiations to acquire DMI BioSciences

Euthymics Bioscience completes $24 million Series A financing

Clinical trial initiated to evaluate LibiGel on cognitive function in menopausal women

Depression increases cardiovascular problems in men with erectile dysfunction

Women aged 27-45 have heightened sex drive in response to dwindling fertility: Study

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

BioSante joins Russell 3000 Index

Palatin announces completion of patient dosing, database lock in bremelanotide study for ED

Health Canada issues Screening Acceptance Letter in connection with NexMed's NDS for Vitaros

BioSante closes $15 million registered direct offering

Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

BioSante announces $15 million registered direct offering

BioSante announces presentation of LibiGel safety update at ENDO 2010

Obesity linked to bad sexual health: French Study

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

Nymox near completion of new NX-1207 follow-up study for BPH

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Newsletters you may be interested in